



ΔΗΜΟΚΡΙΤΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΡΑΚΗΣ



FONDATION SANTÉ

DEPARTMENT OF MOLECULAR BIOLOGY & GENETICS

## Biotechnology Colloquium

at the

**DEMOCRITUS UNIVERSITY OF THRACE**

**DEPARTMENT OF MOLECULAR BIOLOGY & GENETICS**

# BIOTECHNOLOGY IN THE 21<sup>st</sup> CENTURY

Alexandroupolis

*University Hospital Large Lecture Theatre*

Monday, 19 November 2007

## Program

- 10:15 – 10:45**     **Registration** (*Lobby of the Large Lecture Theatre, University Hospital*)
- 10:45 – 11:00**     **Welcome and Opening Remarks**
- 11:00 – 11:10**     **Fondation Santé – Mission and Accomplishments**  
*Fulla Chapple, Executive Director, Fondation Santé, Athens, Greece*
- 11:10 – 11:50**     **Biotechnology – History and Prospects**  
*Stelios Papadopoulos, Chairman, Fondation Santé, New York, NY, USA*
- 11:50 – 12:30**     **Challenges in Biotech Drug Discovery and Development – The Exelixis Story**  
*George Scangos, President & CEO, Exelixis Inc., South San Francisco, CA, USA*
- 12:30 – 13:00**     **Coffee Break**
- 13:00 – 13:30**     **A Short Story about the Greek Diagnostics Industry – Dreams, Efforts and Inhibitors**  
*Sakis Mitropoulos, Director of Customer Services & Chief Scientific Advisor, Medicon Hellas SA, Gerakas Attikis, Greece*
- 13:30 – 14:00**     **Alexander Innovation Zone – Plans for a Biotech Cluster in Thessaloniki**  
*Iordanis Arzimanoglou, CEO, Alexander Innovation Zone, Thessaloniki, Greece*
- 14:00 – 14:30**     **Discussion**  
Moderator: *Sotiria Boukouvala, Lecturer, Department of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece*

*Supported by:*

The University Rector  
The University Research Committee

The Prefectural Government  
of Rodopi-Evros





---

## Speakers

**Fulla Chapple** is the Executive Director of Fondation Santé. She joined the foundation in 2001 and is responsible for institutional development and coordinating the foundation's programs and projects. Ms. Chapple has extensive experience in working for non-profit organizations in various capacities. Before joining Fondation Santé she served as the Fund Raising Consultant for UNHCR (United Nations High Commissioner for Refugees - Athens Branch Office). For several years she served as the Head of Fundraising and Communications for the Greek office of the World Wide Fund for Nature (WWF Greece). She also worked for Emporiki Venture Capital, where she was responsible for the management and administration of the company's regional offices in Eastern Europe and the Balkans. Ms. Chapple began her career as the owner and director of the Athens Conference Center, which she managed for 15 years.

**Dr. Stelios Papadopoulos'** career in biotech and pharma spans more than two decades. Dr. Papadopoulos retired as Vice Chairman of Cowen & Co., LLC in August 2006 after six years with the firm where, as an investment banker, he focused on the biotech and pharma sectors. Prior to joining Cowen, he spent 13 years as an investment banker at PaineWebber, Incorporated where he was most recently Chairman of PaineWebber Development Corp., a PaineWebber subsidiary focusing on biotechnology. He joined PaineWebber in April 1987 from Drexel Burnham Lambert where he was a Vice President in the Equity Research Department covering the biotechnology industry. Prior to Drexel, he was a biotechnology analyst at Donaldson, Lufkin & Jenrette.

Dr. Stelios Papadopoulos is a co-founder and chairman of the Board of Directors of Exelixis, Inc., and he is a co-founder and member of the Board of both, Anadys Pharmaceuticals, Inc. and Cellzome, Inc. He is vice-chairman of the Board of Directors of BG Medicine, Inc. and a member of the Scientific Advisory Board of Symphony Capital. In the not-for-profit sector, Dr. Papadopoulos is a co-founder and Chairman of Fondation Santé, a member of the Board of Visitors of Duke University Medical Center and a member of the Board of Directors of the National Marrow Donor Program (NMDP).

Before coming to Wall Street, Dr. Papadopoulos was on the faculty of the Department of Cell Biology at New York University Medical Center. He continues his affiliation with NYU Medical Center as an Adjunct Associate Professor of Cell Biology. Dr. Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University.

**Dr. George Scangos** received a BA in Biology from Cornell University, a PhD from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Dr. Frank Ruddle at Yale University. While in Dr. Ruddle's laboratory, Dr. Scangos, together with Dr. Jon Gordon, were the first to generate a transgenic mouse. Dr. Scangos then joined the faculty of The Johns Hopkins University, where he currently holds a position as Adjunct Professor. While at Johns Hopkins, Dr. Scangos' laboratory was one of the first to demonstrate that homologous recombination could occur in mammalian cells.

Dr. Scangos left Johns Hopkins in 1986 to work for Bayer Corporation, where he held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division, and then President of Bayer Biotechnology, where he led an integrated group focused on discovery, development, and manufacture of biological products.

Dr. Scangos has served as President and Chief Executive Officer and Board Member of Exelixis since 1996. He currently serves as Chairman of Anadys Pharmaceuticals, and is on the Board of Entelos, Inc. Dr. Scangos is a member of the Board of Visitors of the University of California, San Francisco School of Pharmacy, the Board of Overseers of the University of California, Davis, School of Medicine, and the Advisory Board for the Cornell University Life Sciences Initiative. Dr. Scangos also serves as a member of the Board of the Global Alliance for TB Drug Development.





### DEPARTMENT OF MOLECULAR BIOLOGY & GENETICS

---

**Sakis Mitropoulos** studied biology at the University of Athens. He subsequently received professional training at some of the world's leading companies in the field of clinical diagnostics. He has been instrumental in establishing the first, and only, Greek diagnostics company, Medicon Hellas SA, where he worked for years as R&D manager, developing clinical chemistry and hematology reagents. He currently holds the positions of Director of Customer Services, Chief Scientific Advisor and member of the Board of Directors. He is an active member of the American Association of Clinical Chemistry and the Hellenic Society of Clinical Chemistry-Clinical Biochemistry (HSCC-CB), frequently lecturing in professional training programs. He is engaged in industrial R&D activities in the fields of clinical chemistry and molecular diagnostics, currently working on his Clinical Chemistry PhD in pharmacogenomics.

**Dr. Iordanis Arzimanoglou** was recently appointed CEO of Alexander Innovation Zone, Thessaloniki, Greece. In that role, he is mandated to catalyze development and commercialization of new breakthrough research within the Innovation Zone environment, facilitate the interface between university and industry, and establish critical alliances in the entire Thessaloniki metropolitan area with European and US partners. Special focus is given to biotechnology.

From 2003 until his appointment to his current position, Dr. Arzimanoglou was Director of Biomedico Forum/Biomedical Science Park, a biocluster in Aarhus, Denmark. Prior to that, he served as a consultant to major private hospitals and early stage biotech companies in Belgium, Luxemburg and Greece on management, strategy, research and business development (2001-2002). During the same time, he served as expert evaluator for the Research Directory (DG12), European Commission, Brussels, to review competitive research grant proposals in the field of human genetics.

As an academic, Dr. Arzimanoglou has been an Adjunct Associate Professor with the University of Aarhus, Institute of Human Genetics since 2006. Most recently he was Assistant Professor of Molecular Genetics at Weill Cornell Medical College, New York (1999-2000) and prior to that he was Chief of Cancer Genetics in the Department of Gynecology at Lenox Hill Hospital, New York (1997-99). Before joining Lennox Hill, he was a research scientist in the Division of Human Genetics at Weill Cornell Medical College (1993-96). During the same time he successfully completed the requirements for certification by the American Board of Medical Genetics. Dr. Arzimanoglou earned a BS in biology from the University of Athens, a Graduate Certificate in International Business Management from Boston University and a PhD in Molecular Genetics and Biochemistry from the University of Athens and completed his postdoctoral fellowship in the Department of Medicine at Weill Cornell Medical College (1991-92).

**Dr. Sotiria Boukouvala** has been a Lecturer on Molecular Biology at the Department of Molecular Biology and Genetics of the Democritus University of Thrace since 2006, where she also taught as a visiting lecturer between 2003 and 2005. She has undertaken teaching of the modules Human Genetics (2003-2005), Applied Biotechnology (2004-2006), Cell Biology (2007) and Applications of Molecular Biology in Health Sciences (2007). Her research focus is on the application of genomics to the validation of drug targets. She has experience in pharmacogenomics, acquired through her studies of the molecular genetics of drug-metabolizing enzymes.

Before her appointment at the University of Thrace, Dr. Boukouvala was a research scientist at Exelixis Inc. (2005- 2006), where she investigated the genetic factors causing resistance to novel targeted therapies of cancer. She has also worked in the R&D Department of Medicon Hellas SA (2002-2004), where she developed an innovative system for genetic diagnostics. She holds a PhD from the University of Oxford (2002), where she also worked as a graduate and post-doctoral research assistant (1998-2002), an MS with Distinction from Imperial College of the University of London (1997) and a BS in Biology from the University of Athens (1996). She has been a Fondation Santé Fellow and a Scholar of the National Scholarship Foundation, the Bodossaki Foundation and Imperial College.

---

#### *Supported by:*

The University Rector  
The University Research Committee

The Prefectural Government  
of Rodopi-Evros





ΔΗΜΟΚΡΙΤΕΙΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΘΡΑΚΗΣ

DEPARTMENT OF MOLECULAR BIOLOGY & GENETICS



FONDATION SANTÉ

## Organizers

**Fondation Santé ([www.fondationsante.org](http://www.fondationsante.org))** was established in 2000 as a private foundation operating exclusively for charitable, scientific and educational purposes. Our mission is to improve the health and education of those in need, whether countries, regions or individuals. Fondation Santé seeks to accomplish these objectives through various means including organizing internship programs as well as holding conferences on scientific and healthcare related subjects. The conferences attract leaders in the fields of health, medicine, science, business and finance and provide a forum to exchange ideas and promote research in areas relevant to the health, education and welfare of mankind. Furthermore, the foundation attempts to facilitate communication among governments, pharmaceutical and biotech companies, academic and research organizations, and individuals in order to encourage scientific and medical initiatives that require multidisciplinary or global approaches.

**The Department of Molecular Biology & Genetics ([www.mbg.duth.gr](http://www.mbg.duth.gr))** was established in 2000 and is the only university department in Greece dedicated to providing a comprehensive Molecular Biology and Genetics curriculum to 80-90 undergraduate students admitted each year. It was founded with the vision of becoming a centre of excellence in biosciences and is committed to recruiting young and enthusiastic investigators of international potential who are developing significant research capacity in a relatively neglected corner of Greece. It is currently chaired by the University Rector, Professor K. Simopoulos. The department has sixteen faculty members with research interests spanning Molecular, Cell and Developmental Biology, Genetics, Biochemistry, Biotechnology, Immunology, Molecular Pharmacology, Structural Biology, Bioinformatics and Medicinal Chemistry, and is in the process of recruiting additional teaching, research and support staff. It is one of the newest departments of the Democritus University of Thrace (DUTH), which comprises 18 departments in four prefecture capitals and enrolls over 12,000 undergraduate and postgraduate students. DUTH plays a key role in developing the cultural, scientific and economic profile of the region, contributing to high-level academic education and research in Greece.

For queries about this Colloquium, please contact:

**Dr. Sotiria Boukouvala, Lecturer**

**Tel. +30 25510 30632, Fax. +30 25510 30613, [sboukouv@mbg.duth.gr](mailto:sboukouv@mbg.duth.gr)**

**Supported by:**

The University Rector  
The University Research Committee

The Prefectural Government  
of Rodopi-Evros

